



BioXcel Therapeutics to Present at Upcoming Investor Conferences in April

April 3, 2019

NEW HAVEN, Conn., April 03, 2019 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. ("BTI") (Nasdaq: BTAI) today announced, that the Company will deliver corporate overview presentations at both the H.C Wainwright & Co. Global Life Sciences Conference, April 7-9, 2019 in London, UK and the BioCentury Future Leaders Conference, April 12 in New York, NY. BTI is a clinical stage biopharmaceutical development company utilizing novel artificial intelligence approaches to identify the next wave of medicines across neuroscience and immuno-oncology.

Details of the presentations are below:

Event: H.C. Wainwright & Co. Global Life Sciences Conference

Date: Tuesday, April 9, 2019

Time: 11:10 AM GMT / 7:10 AM EDT

Event: BioCentury Future Leaders Conference

Date: Friday, April 12, 2019

Time: 3:00 PM EDT

A live webcast of the H.C. Wainwright presentation will be accessible through the Investors section of the Company's website at www.bioxccltherapeutics.com for 30 days following the event.

In addition to the presentations, the BTI management will be hosting 1-on-1 investor meetings at the respective conferences. Investors attending either conferences, who are interested in meeting with BTI management should contact their representative for the respective event.

About BioXcel Therapeutics, Inc.:

BioXcel Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on drug development that utilizes novel artificial intelligence to identify the next wave of medicines across neuroscience and immuno-oncology. BTI's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. BTI's two most advanced clinical development programs are BXCL501, a sublingual thin film formulation designed for acute treatment of agitation resulting from neurological and psychiatric disorders, and BXCL701, an immuno-oncology agent designed for treatment of a rare form of prostate cancer and for treatment of pancreatic cancer. For more information, please visit www.bioxccltherapeutics.com.

Contact Information:

BioXcel Therapeutics

The Ruth Group

Lee Roth/ Janhavi Mohite

646-536-7012/ 7026

lrth@theruthgroup.com/ jmohite@theruthgroup.com

Source: BioXcel Therapeutics, Inc.